Trusted Source for Health Articles
Trusted Source for Health Articles
Evidence-based coverage of weight loss drugs, GLP-1 science, metabolic health, and fat loss strategies. Includes the latest research on Ozempic, Mounjaro, Wegovy, tirzepatide, and semaglutide — reviewed by Dr. Ajit Kumar, MD (Medicine) | MA Psychology.
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy In 2023, India crossed 101 million people living with type 2 diabetes – officially surpassing China to become the diabetes capital of the world. The same year, a landmark Lancet projection study modelled that India is […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy If you’ve started noticing more hair in the shower drain or on your pillow a few months into Ozempic, here’s what’s actually going on and what you can do about it — not just the science, […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy I get asked about alcohol and Ozempic almost every week in clinic, and I’ve noticed the questions cluster around the same handful of assumptions — most of them half-right, which is actually worse than being wrong, […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy Millions of people are taking Ozempic, Wegovy, and Mounjaro with impressive results. But a growing body of research is asking a question that very few people in the weight loss conversation are talking about: why do […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy As GLP-1 drugs have dominated health headlines, a provocative question has emerged: if a weekly injection can produce 15-20% body weight loss with minimal effort, is there any point to the gym? Conversely, if someone cannot […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy When tirzepatide (Mounjaro/Zepbound) was approved, it was described as a dual GLP-1/GIP receptor agonist. Most of the attention went to GLP-1 – the hormone semaglutide (Ozempic) also targets, and the one that has dominated obesity medicine […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy Sleep apnea affects an estimated 100 million people worldwide, and India carries a disproportionate burden – with obesity, anatomical factors, and underdiagnosis creating a perfect storm. The standard treatment, CPAP therapy, is effective but poorly tolerated: […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy In August 2023, the New England Journal of Medicine published results that changed cardiovascular medicine. The SELECT trial — the largest randomised trial of a GLP-1 drug in cardiovascular patients, 17,604 people followed for over 3 […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy For the first time in obesity medicine, doctors have two genuinely different classes of injectable weight loss drugs to choose from. Semaglutide (Ozempic/Wegovy) targets one hormone receptor; tirzepatide (Mounjaro/Zepbound) targets two, and produces meaningfully greater average […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy Millions of people have started semaglutide injections and experienced dramatic weight loss. But what happens when they stop? The answer, backed by rigorous clinical data, is uncomfortable – and it has fundamentally changed how doctors think […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy Most patients with kidney disease are told to be cautious with new medications. Yet one of the largest kidney trials ever conducted has just delivered a striking verdict on semaglutide — the drug sold as Ozempic […]
Medically Written & Reviewed By Dr. Ajit Kumar, MD (Medicine) — Founder, Medimadad. About the Author | Editorial Policy Everyone knows Ozempic and Wegovy for one reason: weight loss. But in 2026, a wave of new research is revealing something that is catching even doctors off guard. These GLP-1 receptor agonist drugs are doing far […]
Get free weekly health insights
Join thousands of readers. No spam. Unsubscribe anytime.
Prefer a one-time download? Get our free Weight Management guide →
